GlassScriptPhysician profile
J Cal Noorda
NPI 1073586087
$15,461.40
in general payments reported to CMS, 2019-2025
52 companies · $3,248 in 2025
The $3,248 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.72 · 2020: $1,385 · 2021: $3,388 · 2022: $2,538 · 2023: $2,424 · 2024: $2,435 · 2025: $3,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,967 · Education: $94.00 · Debt Forgiveness: $46.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,966.65 |
| Education | $94.00 |
| Debt Forgiveness | $46.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,929.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,869.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,765.73 | 2020-2025 | |
| Glaxosmithkline, LLC. | $927.00 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $848.57 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $708.94 | 2022-2025 | |
| Lilly USA, LLC | $698.87 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $688.24 | 2021-2025 | |
| Amgen INC. | $607.34 | 2020-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $591.98 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $462.57 | 2020-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.19 | 2022-2025 | Caplyta |
| Abbott Laboratories | $327.80 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Corcept Therapeutics | $275.70 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $269.25 | 2021-2025 | Rexulti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Cal Noorda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.